Obesity drug 5% weight loss endpoint: advisory cmte. okays multiple analytical methods.
This article was originally published in The Tan Sheet
Executive Summary
OBESITY DRUG 5% WEIGHT LOSS ENDPOINT: MULTIPLE ANALYTICAL METHODS could be considered appropriate to support efficacy, FDA's Endocrinologic & Metabolic Drugs Advisory Committee recommended at a July 14 meeting. The committee agreed that different analytical methods could be used to prove whether an obesity drug meets the endpoint criteria of a 5% greater weight loss on drug than placebo so long as the criteria are pre-defined. The discussion was a follow-up to the committee's January recommendation that FDA accept 5% weight loss at one year after initiation of treatment as a clinically meaningful obesity drug effect.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning